Enzymotec improves DHA bioavailability
system, which improves the body's absorption of the fatty acid.
DHA, an omega-3, is increasingly seen as an effective supplement for heart health, as it has been shown to help prevent some of the risk factors associated with heart disease and also for cognitive improvement or maintenance.
The new technology uses phospholipids as DHA carriers to help improve the delivery of DHA and therefore improve its efficacy for health.
"One of today's challenges is to deliver DHA cost effectively and improve its efficacy, while overcoming taste and stability limitations, which are currently associated with DHA," said Dr Tzafra Cohen, head of Enzymotec's technology department.
"We were able to produce a DHA-rich phospholipid conjugate, which mimics the natural form of DHA found in important body tissues such as the brain or the liver and is capable of ensuring of a better delivery of DHA," added Dr Cohen.
Enzymotec said it has concluded an animal and human study on a proprietary structured derivative of the DHA-phospholipid system, exhibiting better availability than fish DHA or mixtures of DHA and phospholipids and consequently a superior biological effect.
